Two-year results of Preserflo Microshunt use in Open-angle Glaucoma Surgery.

Q4 Medicine

Ceska a Slovenska Oftalmologie Pub Date : 2025-01-01 DOI:10.31348/2025/9

Veronika Fialová, Martin Váša, Pavel Rozsíval, Jitka Kalinová, Jan Studnička

{"title":"Two-year results of Preserflo Microshunt use in Open-angle Glaucoma Surgery.","authors":"Veronika Fialová, Martin Váša, Pavel Rozsíval, Jitka Kalinová, Jan Studnička","doi":"10.31348/2025/9","DOIUrl":null,"url":null,"abstract":"Aim: To evaluate the safety and efficacy outcomes of PRESERFLO™ MicroShunt implantation in patients with primary open-angle glaucoma.Material and methods: Retrospective data analysis of 19 eyes of 12 patients, comprising 5 females and 7 males. The patients underwent surgery between August 2020 and February 2022. The follow-up period was 24 months after surgery. During the follow-up period, intraocular pressure (IOP), the need to apply topical antiglaucoma medication and its spectrum, visual field status, optic nerve target findings and postoperative complications were recorded. The indication for PRESERFLO™ MicroShunt implantation was primary open angle glaucoma (POAG), poorly controlled with maximum tolerated medical therapy.Results: Average IOP was reduced from 19.05 ±5.58 mmHg preoperatively to 11.47 ±2.48 mmHg at 3 months postoperatively, 12.26 ±2.48 mmHg at 6 months postoperatively, 14.0 ±2.43 mmHg at 12 months postoperatively, 11.78 ±2.37 mmHg at 18 months postoperatively, and 12.73 ±2.51 mmHg at 24 months postoperatively (p.","PeriodicalId":39839,"journal":{"name":"Ceska a Slovenska Oftalmologie","volume":"81 Ahead of Print","pages":"1-8"},"PeriodicalIF":0.0000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ceska a Slovenska Oftalmologie","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.31348/2025/9","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Aim: To evaluate the safety and efficacy outcomes of PRESERFLO™ MicroShunt implantation in patients with primary open-angle glaucoma.

Material and methods: Retrospective data analysis of 19 eyes of 12 patients, comprising 5 females and 7 males. The patients underwent surgery between August 2020 and February 2022. The follow-up period was 24 months after surgery. During the follow-up period, intraocular pressure (IOP), the need to apply topical antiglaucoma medication and its spectrum, visual field status, optic nerve target findings and postoperative complications were recorded. The indication for PRESERFLO™ MicroShunt implantation was primary open angle glaucoma (POAG), poorly controlled with maximum tolerated medical therapy.

Results: Average IOP was reduced from 19.05 ±5.58 mmHg preoperatively to 11.47 ±2.48 mmHg at 3 months postoperatively, 12.26 ±2.48 mmHg at 6 months postoperatively, 14.0 ±2.43 mmHg at 12 months postoperatively, 11.78 ±2.37 mmHg at 18 months postoperatively, and 12.73 ±2.51 mmHg at 24 months postoperatively (p.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Ceska a Slovenska Oftalmologie Medicine-Ophthalmology

CiteScore

0.80

自引率

0.00%

发文量

期刊介绍： - Redakce přijímá pouze práce vyhovující po odborné stránce, které jsou na odpovídající profesionální a formální úrovni. - Uveřejněná práce se stává majetkem časopisu, přetisknout její část nebo obrázek lze jen s citací původu. - Rukopis zasílejte v originále a dobře čitelné kopii (je nutná také kopie tabulek, legend, podle možnosti i obrázků). - Listy číslujte v pravém horním rohu a spojujte svorkou, nesešívejte. Přijímáme práce psané na jedné straně kvalitního bílého nelesklého papíru formátu A4 (neprůklepový) na psacím stroji nebo počítači s obvyklými typy.